{
    "score": [
        0.8
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "reviewing epizyme and nantkwest ."
    ],
    "id": "261599.train",
    "article": [
        "epizyme and nantkwest are both small-cap healthcare companies , but which is the superior stock ? we will compare the two companies based on the strength of their dividends , analyst recommendations , risk , profitability , institutional ownership , valuation and earnings . profitabilitythis table compares epizyme and nantkwest 's net margins , return on equity and return on assets . net marginsreturn on equityreturn on assetsepizymen/a -67.04 % -53.15 % nantkwest-204,606.36 % -36.21 % -32.04 % risk and volatilityepizyme has a beta of 2 , meaning that its stock price is 100 % more volatile than the s&p 500 . ",
        "comparatively , nantkwest has a beta of 3.41 , meaning that its stock price is 241 % more volatile than the s&p 500 . analyst ratingsthis is a summary of recent ratings for epizyme and nantkwest , as reported by marketbeat . com . sell ratingshold ratingsbuy ratingsstrong buy ratingsrating scoreepizyme01902 .90 nantkwest12102 .00 epizyme currently has a consensus target price of $ 23.00 , indicating a potential upside of 86.23 % . nantkwest has a consensus target price of $ 5.33 , indicating a potential upside of 4.17 % . given epizyme 's stronger consensus rating and higher probable upside , research analysts plainly believe epizyme is more favorable than nantkwest . ",
        "insider & institutional ownership85 .3 % of epizyme shares are held by institutional investors . comparatively , 19.1 % of nantkwest shares are held by institutional investors . 25.2 % of epizyme shares are held by company insiders . comparatively , 70.2 % of nantkwest shares are held by company insiders . strong institutional ownership is an indication that endowments , large money managers and hedge funds believe a stock will outperform the market over the long term . valuation & earningsthis table compares epizyme and nantkwest 's revenue , earnings per share and valuation . gross revenueprice/sales rationet incomeearnings per shareprice/earnings ratioepizyme $ 8.01 million106 .82 - $ 110.21 million-5.44 nantkwest $ 40,000.0010,170.88 - $ 120.80 million-4.03 epizyme has higher revenue and earnings than nantkwest . ",
        "epizyme is trading at a lower price-to-earnings ratio than nantkwest , indicating that it is currently the more affordable of the two stocks . summaryepizyme beats nantkwest on 7 of the 13 factors compared between the two stocks . epizyme company profileepizyme , inc. . is a clinical-stage biopharmaceutical company . the company discovers , develops and plans to commercialize epigenetic therapies for cancer patients . the company is engaged in the discovery and development of novel epigenetic therapies for cancer patients . the company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases . the company develops small molecule inhibitors of other chromatin modifying proteins . ",
        "the company 's lead product candidate , tazemetostat , is a potent and selective inhibitor of the enhancer of zeste homolog 2 histone methyltransferases , an enzyme that plays an important role in various cancers . the company is evaluating tazemetostat in a phase ii study in adults with relapsed or refractory non-hodgkin lymphoma , and one phase i study in children with molecularly defined solid tumors . the company owns the global development and commercialization rights to tazemetostat outside of japan . nantkwest company profilenantkwest , inc. . is a clinical-stage immunotherapy company . the company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer , infectious diseases and inflammatory diseases . ",
        "its immuno-oncology nk platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell ; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody , enabling targeted cell killing through antibody dependent cellular cytotoxicity , and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines ."
    ]
}